December 19, 2018

Patrick Fabbio
Senior Vice President and Chief Financial Officer
Progenics Pharmaceuticals Inc.
One World Trade Center, 47th Floor
New York, NY 10007

       Re: Progenics Pharmaceuticals Inc.
           Form 10-K for the Fiscal Year Ended December 31, 2017
           Filed March 8, 2018
           File No. 000-23143

Dear Mr. Fabbio:

        We have limited our review of your filing to the financial statements
and related
disclosures and have the following comment. In our comment, we may ask you to
provide us
with information so we may better understand your disclosure.

       Please respond to the comment within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe our
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to the comment, we may have additional
comments.

Form 10-K for the Year Ended December 31, 2017

Management's Discussion and Analysis of Financial Condition and Results of
Operations
Results of Operations
Research and Development ("R&D"), page 36

1.    Please provide us a breakdown of your research and development ("R&D")
expenses
      incurred for each year presented by product candidate or project. To the
extent that you do
      not track costs by project, please explain how your R&D costs are managed
and how they
      are reported within the organization. To the extent that you can
distinguish your R&D
      costs by discovery, preclinical and clinical development categories
and/or therapeutic
      class or by the type of cost, please provide us with this information.
Please also tell us
      your consideration of disclosing this information given that you consider
research and
      development to be essential to your business.


       In closing, we remind you that the company and its management are
responsible for the
 Patrick Fabbio
Progenics Pharmaceuticals Inc.
December 19, 2018
Page 2

accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
absence of action by the staff.

       You may contact Ibolya Ignat at 202-551-3636 or Angela Connell at
202-551-3426 with
any questions.



FirstName LastNamePatrick Fabbio                          Sincerely,
Comapany NameProgenics Pharmaceuticals Inc.
                                                          Division of
Corporation Finance
December 19, 2018 Page 2                                  Office of Healthcare
& Insurance
FirstName LastName